Canadian biopharma company Medicago, a subsidiary of Japan’s Mitsubishi Tanabe Pharma (TYO: 4508), and UK pharma major GlaxoSmithKline (LSE: GSK) have announced that Health Canada has granted approval for Covifenz, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
This vaccine, formerly dubbed MT-2766, is indicated for active immunization to prevent coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age.
Medicago received C$173 million ($131 million) from the Canadian government to help develop its plant derived virus-like particle (VLP) vaccine, MT-2766.
“The approval of our COVID-19 vaccine is a significant milestone for Canada in the fight against the pandemic. We appreciate Health Canada’s timely review,” said Takashi Nagao, president and chief executive at Medicago. “We’re also grateful for the government of Canada’s support in the development of this new vaccine, and we are manufacturing doses to start fulfilling its order,” he added.
Roger Connor, president of GSK Vaccines, added, “This first approval is an important milestone in our approach of pairing GSK’s well-established pandemic adjuvant with promising antigens to develop protein-based, refrigerator-stable COVID-19 vaccines to help protect people against COVID-19 disease. We look forward to working with Medicago to make the vaccine available in Canada and to progress further regulatory submissions.”
Government supply contract
The Canadian government has a contract with Medicago (the Marketing Authorization Holder) to supply the COVID-19 vaccine. Medicago says it is committed to fulfilling this order as soon as possible.
“As one of our government’s top priorities has been to reverse the 40-year decline faced by Canada’s biomanufacturing sector, we are pleased to see Medicago’s vaccine approval. It is a great milestone for Canada’s biotechnology sector and for homegrown innovation. We will continue to support companies that want to produce vaccines in Canada and join the growing national biomanufacturing sector.” said François-Philippe Champagne, Canada’s Minister of Innovation, Science and Industry.
Health Canada based its decision on scientific data shared by Medicago as part of their rolling submission that began in April 2021 under an Interim Order, and concluded with the filing of a New Drug Submission-CV.
About Covifenz
Covifenz uses Coronavirus-Like Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs) co-administered with GSK’s pandemic adjuvant. The vaccination regimen calls for two doses given intramuscularly 21 days apart (3.75mcg of CoVLP antigen in combination with GSK pandemic adjuvant in the same injection). The vaccine is stored at 2 °C to 8 °C. Covifenz antigen will be manufactured in Canada and in North Carolina (USA).
Covifenz is not currently approved or authorized for the prevention of COVID-19 or any other indication anywhere other than Canada.
News
Common Medication Could Save Half a Million Lives Each Year – So Why Isn’t It?
A recent study conducted by scientists at the University of Southern California sheds light on the reasons why children are not receiving an affordable and effective diarrhea treatment. Medical professionals in developing nations are [...]
X Marks the Spot: AI’s Treasure Maps Lead to Early Disease Detection
Medical diagnostics expert, doctor’s assistant, and cartographer are all fair titles for an artificial intelligence model developed by researchers at the Beckman Institute for Advanced Science and Technology. Their new model accurately identifies tumors [...]
Scientists Discover Method To Identify Alzheimer’s Disease Before It Progresses to Dementia
Researchers at Aarhus University have discovered a method to identify Alzheimer’s disease before it progresses to dementia, potentially opening up new avenues for treatment. A groundbreaking study could pave the way for early detection [...]
Startling Discovery: COVID-19 Virus Can Stay in the Body More Than a Year After Infection
The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended, according to new research from UC San Francisco that offers potential [...]
New bioengineered protein design shows promise in fighting COVID-19
In the wake of the COVID-19 pandemic, scientists have been racing to develop effective treatments and preventatives against the virus. A recent scientific breakthrough has emerged from the work of researchers aiming to combat [...]
Sugar-coated gold nanoparticles can quickly eliminate bacterial infections, no antibiotics required
If left to their own devices, bacteria on our teeth or wounded skin can encase themselves in a slimy scaffolding, turning into what is called biofilm. These bacteria wreak havoc on our tissue and, [...]
Liquid Lightning: Nanotechnology Unlocks New Energy
EPFL researchers have discovered that nanoscale devices harnessing the hydroelectric effect can harvest electricity from the evaporation of fluids with higher ion concentrations than purified water, revealing a vast untapped energy potential. Evaporation is a natural [...]
Unmasking the Illusion: AI-Generated Faces Challenge Perceptions
Research shows survey participants duped by AI-generated images nearly 40 percent of the time. If you recently had trouble figuring out if an image of a person is real or generated through artificial intelligence [...]
New Discovery Reveals How Cells Defend Themselves During Stressful Situations
Stress granules play a crucial role in the stress response, arising from the aggregation of non-translating mRNAs and proteins. Although significant knowledge exists about stress granules, the mechanisms behind their mRNA localization remain partially [...]
Scientists use a new type of nanoparticle that can both deliver vaccines and act as an adjuvant
Many vaccines, including vaccines for hepatitis B and whooping cough, consist of fragments of viral or bacterial proteins. These vaccines often include other molecules called adjuvants, which help to boost the immune system's response [...]
Not Science Fiction: How Optical Neural Networks Are Revolutionizing AI
A novel architecture for optical neural networks utilizes wavefront shaping to precisely manipulate the travel of ultrashort pulses through multimode fibers, enabling nonlinear optical computation. Present-day artificial intelligence systems rely on billions of adjustable [...]
Turning skin cells into limb cells sets the stage for regenerative therapy
In a collaborative study, researchers from Kyushu University and Harvard Medical School have identified proteins that can turn or “reprogram” fibroblasts — the most commonly found cells in skin and connective tissue — into [...]
AI reveals prostate cancer is not just one disease
Artificial Intelligence has helped scientists reveal a new form of aggressive prostate cancer, which could revolutionise how the disease is diagnosed and treated in the future. A Cancer Research UK-funded study, published in Cell Genomics, has revealed [...]
New Study Finds That Persistent COVID-19 Infections Are Surprisingly Common
Recent research conducted by the University of Oxford has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more. The findings have been published in the journal Nature. [...]
Innovative nanosheet method revolutionizes brain imaging for multi-scale and long-term studies
The human brain has billions of neurons. Working together, they enable higher-order brain functions such as cognition and complex behaviors. To study these higher-order brain functions, it is important to understand how neural activity [...]
Scientists Have Discovered a Potential Universal Antivenom
Scientists at Scripps Research identified antibodies that protect against a host of lethal snake venoms. Scripps Research scientists have developed an antibody that can block the effects of lethal toxins in the venoms of [...]